Ketamine, one of the most common NMDA receptor antagonists

NMDA receptor antagonists and depression | Abcam

The NMDA Glutamate Receptors Part 1 ..

A number ofexperimental drugs are being investigated for Parkinsons diseasebecause they block the actions of glutamate, an amino acid that is aparticularly potent nerve cell killer. Some of these drugs block areceptor group to glutamate called N-methyl-D-aspartate (NMDA).Investigative NMDA antagonists include remacemide, memantine, riluzole,and budipine. Budipine is of particular interest. It not only blocksNMDA, but it increases levels of two enzymes involved in the productionof dopamine. Studies suggest that it reduces tremor in PD and itproving to be beneficial in combination with levodopa.

Review: NMDA Receptor Hypofunction and Its …

"HD researchers believe that memantine may havestrong potential to slow the progression of HD by decreasing the NMDAreceptor´s sensitivity to glutamate. Memantine is an NMDAantagonist. As an antagonist, memantine prevents the excessive bindingof glutamate to NMDA receptors, inhibiting the pathway to excessiveNMDA activation and nerve cell death. Memantine is also anon-competitive antagonist. "Non-competitive" means that memantinebinds to a site on the NMDA receptor that is different fromglutatmate´s binding site. By binding to one portion of the NMDAreceptor, memantine changes the overall shape of the receptor, makingit more difficult for glutamate to bind to the other portion of thereceptor."

AB - A well established model for the pathophysiology of schizophrenia postulates a role for the NMDA-mediated glutamate transmission. The human gene coding for the 2B subunit of the NMDA receptor (GRIN2B) is considered a candidate based on its selective expression in brain. To evaluate the hypothesis that GRIN2B acts as a major gene in determining susceptibility to schizophrenia, a case-control association study was performed. Five single nucleotide polymorphisms (SNPs) were genotyped in 188 Italian patients and 156 control subjects. The association study showed a marginally significant excess of homozygosity for the polymorphism located in the 3′UTR region (P = 0.04). No other difference in genotype and allele frequencies was found in schizophrenics as compared to the control series. The case-control study was also carried out on estimated haplotypes, confirming a trend for association (P = 0.04). These results suggest that GRIN2B variations might be linked with susceptibility to schizophrenia. Replication studies on larger samples are warranted to further test this hypothesis.


Memantine binding to a superficial site on NMDA …

"Alexander hypothesizes that in epilepsypatients, the protective receptors may not function well or thatglutamate production may be abnormal. A treatment that targets theseprotective glutamate receptors has the potential to block the pathwayinvolved in seizures, with the added benefit of allowing normalcommunication to continue."

Anti-N-methyl-d-aspartate receptor encephalitis: review …

(RMC) is adrug that Huntington's disease (HD) researchers hope can alleviateglutamate toxicity in thebrains of HD patients. Remacemide is an – it inhibits the binding of glutamate to NMDA receptors, preventingglutamate from exerting its toxic effects on the . Although, it has been shown to transiently improve motorperformance in mouse models of HD, the few human clinical trials thathave been performed have not produced statistically significantimprovements in brain or motor function. Patients have also experiencedside effects such as lightheadedness, dizziness, vomiting, nausea, and disturbance...

glutamatergic transmission and NMDA receptor ..

A well established model for the pathophysiology of schizophrenia postulates a role for the NMDA-mediated glutamate transmission. The human gene coding for the 2B subunit of the NMDA receptor (GRIN2B) is considered a candidate based on its selective expression in brain. To evaluate the hypothesis that GRIN2B acts as a major gene in determining susceptibility to schizophrenia, a case-control association study was performed. Five single nucleotide polymorphisms (SNPs) were genotyped in 188 Italian patients and 156 control subjects. The association study showed a marginally significant excess of homozygosity for the polymorphism located in the 3′UTR region (P = 0.04). No other difference in genotype and allele frequencies was found in schizophrenics as compared to the control series. The case-control study was also carried out on estimated haplotypes, confirming a trend for association (P = 0.04). These results suggest that GRIN2B variations might be linked with susceptibility to schizophrenia. Replication studies on larger samples are warranted to further test this hypothesis.

NMDA receptor hypofunction was described in patients with ..

A number ofexperimental drugs are being investigated for Parkinsons diseasebecause they block the actions of glutamate, an amino acid that is aparticularly potent nerve cell killer. Some of these drugs block areceptor group to glutamate called N-methyl-D-aspartate (NMDA).Investigative NMDA antagonists include remacemide, memantine, riluzole,and budipine."